Anne-Kathrin Garz

The target landscape of clinical kinase drugs

Susan Klaeger, Stephanie Heinzlmeir, Mathias Wilhelm et al. · Science · 2017 · 845 citations · Full text

Tumor Biology, Proteomicsdb Database, Drug Target +14

Immunomodulatory drugs disrupt the cereblon–CD147–MCT1 axis to exert antitumor activity and teratogenicity

Ruth Eichner, Michael Heider, Vanesa Fernández‐Sáiz et al. · Nature Medicine · 2016 · 180 citations

Cancer Immunosurveillance, Oncology, Antitumor Activity +13

The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma

Michael Heider, Ruth Eichner, Jacob Stroh et al. · Molecular Cell · 2021 · 61 citations · Full text

Direct modulation of the bone marrow mesenchymal stromal cell compartment by azacitidine enhances healthy hematopoiesis

Catharina Wenk, Anne-Kathrin Garz, Sonja Grath et al. · Blood Advances · 2018 · 41 citations · Full text

Azacitidine combined with the selective FLT3 kinase inhibitor crenolanib disrupts stromal protection and inhibits expansion of residual leukemia-initiating cells in <i>FLT3</i>-ITD AML with concurrent epigenetic mutations

Anne-Kathrin Garz, Saskia Wolf, Sonja Grath et al. · Oncotarget · 2017 · 14 citations · Full text